Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
) as add-on therapy to optimised standard antispasticity treatment in patients with moderate to severe multiple sclerosis (MS) spasticity. METHODS: as add-on therapy vs. further optimised first-line ANTispastics (SAVANT) was a two-phase trial. In Phase A, eligible patients received add-on THC:CBD spray for 4 weeks to identify initial responders [≥20% improvement from baseline in spasticity 0-10 numerical rating scale (NRS) score]. Following washout, eligible initial responders were randomised to receive THC:CBD spray or placebo for 12 weeks (double-blinded, Phase B). Optimisation of underlying antispasticity medications was permitted in both groups across all study periods. RESULTS: Of 191 patients who entered Phase A, 106 were randomised in Phase B to receive add-on THC:CBD spray (n = 53) or placebo (n = 53). The proportion of clinically relevant responders after 12 weeks (≥30% NRS improvement; primary efficacy endpoint) was significantly greater with THC:CBD spray than placebo (77.4 vs. 32.1%; p < 0.0001). Compared with placebo, THC:CBD spray also significantly improved key secondary endpoints: changes in mean spasticity NRS (p < 0.0001), mean pain NRS (p = 0.0013), and mean modified Ashworth's scale (p = 0.0007) scores from Phase B baseline to week 12. Adverse events, when present, were mild/moderate and without new safety concerns. CONCLUSIONS: Add-on THC:CBD oromucosal spray provided better and clinically relevant improvement of resistant MS spasticity compared with adjusting first-line antispasticity medication alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Prevalence and treatment of spasticity reported by multiple sclerosis patients
Rizzo, M. A., Hadjimichael, O. C., Preiningerova, J., & Vollmer, T. L. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1085oa · Cited by 552
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475 · cited 7×
“[16] where the absence of a washout period between Phases A and B may have contributed to a more pronounced placebo effect [16].”
BackgroundMethodResultInfluentialNatural History of Multiple Sclerosis Symptoms
Kister, I., Bacon, T. E., Chamot, E., Salter, A. R., Cutter, G. R., Kalina, J. T., & Herbert, J. (2013) · International Journal of MS Care · doi:10.7224/1537-2073.2012-053 · Cited by 450 · cited 1×
“This might relate to the study power (the sample size was calculated for the primary endpoint) and also to the parameters per se and to the nature of MS spasticity as being one of many symptoms of MS [3].”
BackgroundRandomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S., & for the Sativex Spasticity in MS Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01639.x · Cited by 379 · cited 1×
“In accordance with standard procedures for preapproval regulatory studies in which changes in factors other than target medication must be kept to a minimum, no alterations to underlying antispasticity medications were permitted in previous clinical development trials of THC:CBD spray [15,16,21].”
MethodCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283 · cited 1×
“In accordance with standard procedures for preapproval regulatory studies in which changes in factors other than target medication must be kept to a minimum, no alterations to underlying antispasticity medications were permitted in previous clinical development trials of THC:CBD spray [15,16,21].”
MethodTreatments for spasticity and pain in multiple sclerosis: a systematic review
Beard, S., Hunn, A., & Wight, J. (2003) · Health Technology Assessment · doi:10.3310/hta7400 · Cited by 266
Farrar, J. T., Troxel, A. B., Stott, C., Duncombe, P., & Jensen, M. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.011 · Cited by 252 · cited 1×
“4% of those allocated to THC:CBD spray in Phase B achieved the CID threshold of 30% NRS improvement [20].”
BackgroundA Review of Spasticity Treatments: Pharmacological and Interventional Approaches
Chang, E., Ghosh, N., Yanni, D., Lee, S., Alexandru, D., & Mozaffar, T. (2013) · Critical Reviews in Physical and Rehabilitation Medicine · doi:10.1615/critrevphysrehabilmed.2013007945 · Cited by 233
Otero-Romero, S., Sastre-Garriga, J., Comi, G., Hartung, H.-P., Soelberg Sørensen, P., Thompson, A. J., Vermersch, P., Gold, R., & Montalban, X. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643600 · Cited by 162
Cited by
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
“Another study proposes that Sativex is even more effective at improving MS spasticity than first line antispasticity treatment alone [191].”
BackgroundWang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
Fisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E., Rice, A. S. C., Rowbotham, M., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000001929 · Cited by 215
“A further study reported results of an enriched enrolment study in 107 patients over 12 weeks; mean pain was significantly lower with nabiximols than placebo.(40)”
BackgroundResultInfluentialSafety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Friedman, D., French, J. A., & Maccarrone, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30032-8 · Cited by 203
Metadata
- Authors
- Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C.
- Affiliations
- Neurology Department, Thomayer's Hospital, Praha, Czechia;
- O. Meany Consultancy GmbH, Hamburg, Germany;
- Almirall (Germany) (DE)
- Almirall (Spain) (ES)
- ORCID
- Essner, Ute
- Venue
- International Journal of Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2018-09-13
- Volume
- 129
- Issue
- 2
- Pages
- 119-128
- ISSN
- 0020-7454 (ISSN-L)
- 1543-5245
- OpenAlex
- W2803556125
- Cited by
- 151
- References
- 26
- Citations by year
- 2026: 12 · 2025: 4 · 2024: 21 · 2023: 19 · 2022: 40 · 2021: 22 · 2020: 25 · 2019: 8
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Almirall Hermal GmbH and Almirall S.A.
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- Sativex, multiple sclerosis, spasticity, adjunctive therapy, pain, Ashworth scale
- MeSH terms
- Cannabidiol, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Parasympatholytics, Prospective Studies, Dronabinol, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. https://app.cochat.ai/papers/10.1080/00207454.2018.1481066
- The paper
- Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019). Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience. https://doi.org/10.1080/00207454.2018.1481066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.